Efficacy and tolerability of Brivaracetam in people with intellectual disability compared to those without intellectual disability

Introduction: In England, nearly a quarter of people with intellectual disability (PwID) have epilepsy. Though 70 % of PwID have pharmaco-resistant seizures only 10 % are prescribed anti-seizure medication (ASMs) licenced for pharmaco-resistance. Brivaracetam (BRV) licenced in 2016 has had nine post -marketing studies involving PwID. These studies are limited either by lack of controls or not looking at outcomes based on differing levels of ID severity. This study looks at evidence comparing effectiveness and side-effects in PwID to those without ID prescribed Brivaracetam (BRV). Methods: Pooled case note data for patients prescribed BRV (2016 -2022) at 12 UK NHS Trusts were analysed. Demographics, starting and maximum dose, sideeffects, dropouts and seizure frequency between ID (mild vs. moderate-profound (M/P)) and general population for a 12-month period were compared. Descriptive analysis, Mann-Whitney, Fisher 's exact and logistic regression methods were employed. Results: 37 PwID (mild 17 M/P 20) were compared to 102 without ID. Mean start and maximum dose was lower for PwID than non -ID. Mean maximum dose reduced slightly with ID severity. No difference was found between ID and non -ID or between ID groups (Mild vs M/P) in BRV 's efficacy i.e. >50 % seizure reduction or tolerability. Mental and behavioural side-effects were more prevalent for PwID (27.0 % ID, 17.6 % no ID) but not significantly higher (P = 0.441) or associated with ID severity (p = 0.255). Conclusion: This is the first study on BRV, which compares ID cohorts with differing severity and non -ID. Efficacy, tolerability and side-effects reported are similar across differing ID severity to those with no ID.